The shift from glycolysis to OxPhos has also been showed upon MYC/KRAS or MYC/ERBB2 removal in breast cancer cells (316, 317), and also in glioma cells because of the acquired resistance to phosphoinositide-3-kinase (PI3K) (318). This evidence concerns the gene ERBB2 and breast cancer.